...
机译:尼林尼布在日本特发性肺纤维化患者中:突然的亚组分析? 随机试验
Department of Pulmonary Medicine and OncologyGraduate School of Medicine Nippon Medical;
Department of Respiratory Medicine and AllergyTosei General HospitalAichi Japan;
Clinical Research CenterNational Hospital Organization Kinki‐Chuo Chest Medical CenterOsaka Japan;
Department of Respiratory Medicine and AllergyTosei General HospitalAichi Japan;
Department of Respiratory MedicineKanagawa Cardiovascular and Respiratory CenterKanagawa Japan;
Department of Respiratory MedicineToho University Omori Medical CenterTokyo Japan;
Nippon Boehringer Ingelheim Co. Ltd.Tokyo Japan;
Nippon Boehringer Ingelheim Co. Ltd.Tokyo Japan;
Division of Pulmonary Medicine Department of MedicineJichi Medical UniversityTochigi Japan;
Research Institute of TuberculosisJapan Anti‐tuberculosis AssociationTokyo Japan;
forced vital capacity; idiopathic pulmonary fibrosis; Japanese; nintedanib;
机译:尼林尼布在日本特发性肺纤维化患者中:突然的亚组分析? 随机试验
机译:剂量减少和中断对特发性肺纤维化患者(IPF)中尼丁尼的疗效的影响:临床试验的亚组分析
机译:剂量减少和中断对特发性肺纤维化患者(IPF)中尼丁尼的疗效的影响:临床试验的亚组分析
机译:U放射组学可预测特发性肺纤维化患者的生存
机译:特发性肺纤维化患者使用Gadofosveset增强肺磁共振成像测得的血管渗漏与纤维化的放射学和生理学指标的相关性。
机译:在美国使用吡非尼酮和nintedanib相关的患者和部位特征;肺纤维化基金会患者登记处登记的特发性肺纤维化患者的分析
机译:无论用剂量:inspolsis-on-on-On的亚组分析,M33 Nintedanib的长期疗效是维持在特发性肺纤维化(IPF)的患者中